Iovance Biotherapeutics I...

NASDAQ: IOVA · Real-Time Price · USD
2.60
0.15 (6.12%)
At close: Aug 15, 2025, 1:06 PM

Iovance Biotherapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
164.07M 1.19M n/a n/a
Cost of Revenue
124M 10.76M 21.14M 13.98M
Gross Profit
40.08M -9.57M -21.14M -13.98M
Operating Income
-395.28M -460.56M -398.88M -342.7M
Interest Income
20.27M 13.04M 2.98M 451K
Pretax Income
-375M -447.52M -395.89M -342.25M
Net Income
-372.18M -444.04M -395.89M -342.25M
Selling & General & Admin
153.02M 106.92M 104.1M 83.66M
Research & Development
282.34M 344.08M 294.78M 259.04M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
435.35M 450.99M 398.88M 342.7M
Interest Expense
n/a n/a 2.98M n/a
Selling & Marketing Expenses
101.22M 79.22M n/a n/a
Cost & Expenses
559.35M 461.75M 398.88M 342.7M
Income Tax Expense
-2.83M -3.48M n/a n/a
Shares Outstanding (Basic)
289.88M 235.13M 159.26M 153.41M
Shares Outstanding (Diluted)
289.88M 235.13M 159.26M 153.41M
EPS (Basic)
-1.28 -1.89 -2.49 -2.23
EPS (Diluted)
-1.28 -1.89 -2.49 -2.23
EBITDA
-351.67M -427.43M -374.76M -328.27M
EBIT
-395.28M -460.56M -395.89M -342.25M
Depreciation & Amortization
43.61M 33.13M 21.14M 13.98M